



EarlyTect[®] Bladder Cancer

Detection (BCD) and Monitor (BCM)

Urine Based
Bladder Cancer Test

EarlyTect[®] BC is a non-invasive urine biomarker test, designed to detect the presence of bladder cancer in individuals with hematuria or under surveillance.


promisDX

EarlyTect® BCD

Bladder Cancer Detection

Improves Diagnostic Decision Making and Identify Patients Who May Benefit from Cystoscopy and Biopsy

EarlyTect® BCD is a non-invasive urine test that enhances decision making for other procedures, such as cystoscopy and biopsy.



Performance of EarlyTect® BCD for hematuria patients


	RETROSPECTIVE STUDY	PROSPECTIVE STUDY (2 centers)	PROSPECTIVE STUDY (9 centers)
# of enrolled subjects	105 subjects	204 subjects	300 subjects
Performance	Sensitivity: 87.3%* & 92.3%# Specificity: 95.2%	Sensitivity: 83.3%* & 100%# Specificity: 91.1%	Sensitivity: 89.8%* & 95.1%# Specificity: 92.8% PPV: 58.2% NPV: 98.8%

*: Overall, #: Ta-HG and higher stages

EarlyTect® Bladder Cancer Detection was evaluated in the prospective and retrospective studies. Subjects included individuals with symptoms of gross- and micro-hematuria. Results of **EarlyTect® BCD** delivered a high sensitivity and NPV for Ta high-grade or advanced stage of bladder cancer.

Aids in Detecting Recurrence of Bladder Cancer for Patients Diagnosed and Treated for the Disease

EarlyTect[®] BCM is a non-invasive urine test that accurately rules out patients who do not have recurrent BC, allowing low-risk patients to safely undergo cystoscopy at a longer-than-current interval.




Performance of EarlyTect[®] BCM under surveillance

	RETROSPECTIVE STUDY	PROSPECTIVE STUDY
# of enrolled subjects	83 subjects	105 subjects
Performance	Sensitivity: 83.3% Specificity: 100%*	Sensitivity: 76.3% Specificity: 85.0% PPV: 70.3% NPV: 88.5%

*: Healthy individuals

EarlyTect[®] Bladder Cancer Monitor was evaluated in the prospective and retrospective studies. Subjects included individuals who were diagnosed with bladder cancer and TURBT. Results of **EarlyTect[®] BCM** delivered a high sensitivity and NPV for recurrent bladder cancer.

Benefits



- **Non-invasive:** It does not require any invasive procedures such as biopsies or surgeries. This makes it a less painful and less risky option.
- **Convenient:** Simple and easy to collect and can be done at home or at the doctor's office.
- **Early detection:** Urine tests are highly sensitive and can detect bladder cancer in its early stages.
- **Cost-effective:** Less expensive than other diagnostic tests, such as cystoscopy or biopsies, making it a more cost-effective option.

Partner with Promis Dx for improved management and treatment decisions for your bladder cancer patients.

LEARN MORE about the EarlyTect[®] BCD & EarlyTect[®] BCM

by contacting Promis Dx customer service at (949) 687-1212 or info@promisdx.com.



Promis Diagnostics Inc.

1 Post, Suite 100 Irvine, CA, 92618

Tel: 949.687.1212 / Email : info@promisdx.com